PeriVision, Bioscibex and Carewell receive support from FIT
Summary
Perivision and its software combining artificial intelligence and complex algorithms to carry out vision examinations, Bioscibex and its innovative bioreactor for drug production, and Carewell and its platform connecting the needs of health and care facilities with available qualified personnel. Thanks to its speed of analysis, ease of use and automated instructions, the PeriVision system is helping to increase the flow of optometry and ophthalmology patients by 30%.The CHF 300,000 Tech Growth loan granted by FIT will be used by PeriVision to win more customer contracts, as well as to develop and integrate new functionalities into its system (new tests, diagnostics and prognoses algorithms).Bioscibex and its bioreactor, transforming the way drugs are producedBiomedicines have been shown to be effective in treating many diseases, including autoimmune diseases and cancer. Thanks to a unique combination of two-axis movements, the bioreactor developed by Bioscibex offers the widest volume range on the market, enabling cell expansion from 30 mL to 30 L in a single step.With the CHF 100,000 Tech Seed loan received from FIT, Bioscibex will continue to invest in the research and development of its beta prototype for customer testing. As a result, there is no match between the needs of care structures and the people who can potentially be mobilised to cover them.In light of this observation, Carewell has developed a platform that brings these two areas together and enables their respective needs to converge: managing replacements for healthcare establishments and, for health professionals, to find flexible jobs in the healthcare sector that match their expectations. These three modules will remove the friction from the recruitment process and help to resolve the shortage.After awarding a Digital Grant of CHF 20,000 in 2024, FIT is reiterating its support for Carewell via a Digital Seed loan of CHF 50,000, which will support the next stages in the development of the platform and the costs associated with marketing and recruiting additional freelancers.